Evidence map›Paper›PMID 37129745›Full record

ArticleApplied biochemistry and biotechnology2023

Salvigenin Suppresses Hepatocellular Carcinoma Glycolysis and Chemoresistance Through Inactivating the PI3K/AKT/GSK-3β Pathway.

Hui Shao, Jingyan Chen, Ali Li, Lili Ma, Yongzhi Tang, Huazhong Chen, Yongping Chen, Junyan Liu

Open access · hybridAbstract read
In one paragraph

Article in Applied biochemistry and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 1 pooled it
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. A Comprehensive Review ofDrug design, development and therapy · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Protective effects ofCytotechnology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Application of network pharmacology in synergistic action of Chinese herbal compounds.Theory in biosciences = Theorie in den Biowissenschaften · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hui Shao *Department of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China.
Jingyan Chen *Department of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China.
Ali LiDepartment of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China.
Lili MaDepartment of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China.
Yongzhi TangDepartment of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China.
Huazhong ChenDepartment of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China.
Yongping ChenDepartment of Infectious and Liver Diseases, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang Province, China. cyp@wmu.edu.cn.
Junyan LiuDepartment of Infection, Zhejiang Taizhou Hospital Affiliated to Wenzhou Medical University, Linhai City, 317000, Zhejiang Province, China. liujy087@163.com.
Wenzhou Medical University · CNZhejiang Taizhou Hospital · CNFirst Affiliated Hospital of Wenzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Salvigenin is a Trimethoxylated Flavone enriched in Scutellariae Barbatae Herba and Scutellariae Radix and is demonstrated to have anti-tumor properties in colon cancer. Notwithstanding, the function and mechanism of Salvigenin in hepatocellular carcinoma (HCC) are less well studied. Different doses of Salvigenin were taken to treat HCC cells. Cell viability, colony formation ability, cell migration, invasion, apoptosis, glucose uptake, and lactate production levels were detected. As shown by the data, Salvigenin concentration dependently dampened HCC cell proliferation, migration, and invasion, weakened glycolysis by abating glucose uptake and lactate generation, and suppressed the profiles of glycolytic enzymes. Moreover, Salvigenin strengthened HCC cells' sensitivity to 5-fluorouracil (5-FU) and attenuated HCC 5-FU-resistant cells' resistance to 5-FU. Through network pharmacological analysis, we found Salvigenin potentially regulates PI3K/AKT pathway. As shown by the data, Salvigenin repressed the phosphorylated levels of PI3K, AKT, and GSK-3β. The PI3K activator 740Y-P induced PI3K/AKT/GSK-3β pathway activation and promotive effects in HCC cells. However, Salvigenin substantially weakened 740Y-P-mediated effects. In-vivo assay revealed that Salvigenin hampered the growth and promoted apoptosis of HCC cells in nude mice. Collectively, Salvigenin impedes the aerobic glycolysis and 5-FU chemoresistance of HCC cells by dampening the PI3K/AKT/GSK-3β pathway.

Indexed as

Carcinoma, HepatocellularFlavonesLiver NeoplasmsAnimalsApoptosisCell Line, TumorCell ProliferationDrug Resistance, NeoplasmFluorouracilGlucoseGlycogen Synthase Kinase 3 betaGlycolysisLactatesMiceMice, NudePhosphatidylinositol 3-KinasesFlavonesFluorouracilGlucoseGlycogen Synthase Kinase 3 betaLactatesPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktsalvigeninApoptosisChemoresistanceGlycolysisHepatocellular carcinomaPI3KSalvigenin

Identifiers

PMID37129745
PMCPMC10354167
OpenAlexW4367669423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.